Benefice and pitfall of direct oral anticoagulants in very high-risk myeloproliferative neoplasms - Centre de recherche Saint-Antoine - UMR S938 Access content directly
Journal Articles (Review Article) Thrombosis Research Year : 2022

Benefice and pitfall of direct oral anticoagulants in very high-risk myeloproliferative neoplasms

Laura Herbreteau
  • Function : Author
Lenaïg Le Clech
  • Function : Author
Geoffrey Garcia
  • Function : Author
Chloé James
  • Function : Author
Brigitte Pan-Petesch
  • Function : Author
Francis Couturaud
  • Function : Author
Eric Lippert
Jean-Christophe Ianotto
  • Function : Author

Abstract

Thrombotic and hemorrhagic complications are related to a significant rate of morbidity and mortality in patients with myeloproliferative neoplasms (MPNs), they are therefore called “thrombohemorrhagic” syndromes. Several clinical factors, such as age and presence of cardiovascular comorbidities are responsible for thrombotic complications. High blood counts, platelet alterations, presence of JAK2 mutation and possibly of other CHIP mutations such as TET2, DNMT3A, and ASXL1, procoagulant microparticles, NETs formation, endothelial activation and neo-angiogenesis are some of the parameters accounting for hypercoagulability in patients with myeloproliferative neoplasms. Bleeding complications emerge as a result of platelet exhaustion. They can be also linked to a functional deficiency of von Willebrand factor, when platelet counts rise above 1000G/L. The mainstay of management consists on preventing hemostatic complications, by antiplatelet and/or anticoagulant treatment and myelosuppressive agents in high-risk patients.Circumstances related to a high thrombohemorrhagic risk, such as pregnancy and the perioperative period, prompt for specific management with regards to anticoagulation and myelosuppression treatment type. In order to apply a patient-specific treatment strategy, there is a need for a risk score assessment tool encompassing clinical parameters and hemostasis biomarkers.
Fichier principal
Vignette du fichier
S0049384822002894.pdf (620.73 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-03992708 , version 1 (22-07-2024)

Licence

Identifiers

Cite

Laura Herbreteau, Loula Papageorgiou, Lenaïg Le Clech, Geoffrey Garcia, Chloé James, et al.. Benefice and pitfall of direct oral anticoagulants in very high-risk myeloproliferative neoplasms. Thrombosis Research, 2022, 216, pp.25-34. ⟨10.1016/j.thromres.2022.05.015⟩. ⟨hal-03992708⟩
7 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More